Engineered biomimetic nanoparticles achieve targeted delivery and efficient metabolism-based synergistic therapy against glioblastoma.

Biomimetics Brain Neoplasms / drug therapy Cell Line, Tumor Glioblastoma / drug therapy Glioma Humans Hydrogen Peroxide Nanoparticles

Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
21 07 2022
Historique:
received: 07 07 2021
accepted: 29 06 2022
entrez: 21 7 2022
pubmed: 22 7 2022
medline: 26 7 2022
Statut: epublish

Résumé

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. Here, building on the observation of elevated lactate (LA) in resected GBM, we develop biomimetic therapeutic nanoparticles (NPs) that deliver agents for LA metabolism-based synergistic therapy. Because our self-assembling NPs are encapsulated in membranes derived from glioma cells, they readily penetrate the blood-brain barrier and target GBM through homotypic recognition. After reaching the tumors, lactate oxidase in the NPs converts LA into pyruvic acid (PA) and hydrogen peroxide (H

Identifiants

DOI: 10.1038/s41467-022-31799-y PMID: 35864093 PMC: PMC9304377
pubmed: 35864093
doi: 10.1038/s41467-022-31799-y
pii: 10.1038/s41467-022-31799-y
pmc: PMC9304377
doi:

Substances chimiques

Hydrogen Peroxide BBX060AN9V

Banques de données

figshare
['10.6084/m9.figshare.19825075.v1', '10.6084/m9.figshare.19825096.v1']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4214

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2022. The Author(s).

Références

Mol Cell Biol. 1983 Apr;3(4):539-50
pubmed: 6406835
Nat Med. 2012 Oct;18(10):1580-5
pubmed: 22983397
Cells. 2020 Oct 16;9(10):
pubmed: 33081387
Nat Commun. 2018 Mar 23;9(1):1208
pubmed: 29572438
Cancer Res. 2011 Nov 15;71(22):6921-5
pubmed: 22084445
J Nutr Biochem. 2015 Nov;26(11):1298-307
pubmed: 26298192
Nature. 2017 Nov 2;551(7678):115-118
pubmed: 29045397
Adv Drug Deliv Rev. 2014 Feb;66:42-57
pubmed: 24060923
Adv Mater. 2020 Jul;32(29):e2001459
pubmed: 32484308
Nucleic Acids Res. 2019 Dec 2;47(21):11132-11150
pubmed: 31598701
Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):2037-42
pubmed: 20133848
Pharmacol Rev. 2018 Jul;70(3):412-445
pubmed: 29669750
J Clin Invest. 2013 Sep;123(9):3685-92
pubmed: 23999443
Drug Discov Today. 2019 May;24(5):1193-1201
pubmed: 30878561
Nat Rev Clin Oncol. 2018 Feb;15(2):112-125
pubmed: 29158591
Adv Mater. 2018 Nov;30(46):e1801362
pubmed: 30066406
Nat Commun. 2020 Feb 4;11(1):698
pubmed: 32019928
Nat Biomed Eng. 2019 Jul;3(7):509-519
pubmed: 31148598
Adv Sci (Weinh). 2018 Nov 12;6(3):1801733
pubmed: 31168441
Nat Commun. 2017 Nov 6;8(1):1322
pubmed: 29109438
Chem Sci. 2019 Apr 2;10(18):4847-4853
pubmed: 31183034
Chem Soc Rev. 2016 Nov 21;45(23):6488-6519
pubmed: 27722560
Angew Chem Int Ed Engl. 2020 Nov 23;59(48):21562-21570
pubmed: 32779303
Neurosurg Rev. 2015 Apr;38(2):217-26; discussion 226-7
pubmed: 25468012
Nat Commun. 2018 Nov 14;9(1):4777
pubmed: 30429468
Science. 2020 Apr 10;368(6487):
pubmed: 32273439
Nat Nanotechnol. 2017 Jul;12(7):692-700
pubmed: 28650441
Chem Soc Rev. 2019 Jun 4;48(11):2967-3014
pubmed: 31089607
Adv Mater. 2021 Feb;33(7):e2005562
pubmed: 33432702
J Clin Invest. 2008 Dec;118(12):3930-42
pubmed: 19033663
Mol Cell. 2003 Sep;12(3):735-46
pubmed: 14527418
Mater Des. 2020 Jul;192:108742
pubmed: 32394995
ACS Nano. 2019 Jan 22;13(1):386-398
pubmed: 30576599
Adv Funct Mater. 2020 Oct 28;30(44):
pubmed: 34211358
Nat Commun. 2018 Nov 28;9(1):5044
pubmed: 30487569
Nat Chem. 2020 Dec;12(12):1102-1114
pubmed: 33219365
Sci Transl Med. 2020 Jun 24;12(549):
pubmed: 32581131
ACS Nano. 2020 Jul 28;14(7):8392-8408
pubmed: 32551496
Nat Cell Biol. 2019 Mar;21(3):397-407
pubmed: 30778219
Cancers (Basel). 2020 Nov 03;12(11):
pubmed: 33153193
Curr Oncol Rep. 2017 Nov 2;19(12):84
pubmed: 29098465
Nat Nanotechnol. 2021 May;16(5):538-548
pubmed: 33526838
Adv Mater. 2016 Feb 10;28(6):1312-8
pubmed: 26479864
Clin Cancer Res. 2018 Feb 15;24(4):737-743
pubmed: 28814435
Pharmacol Ther. 2015 Aug;152:63-82
pubmed: 25944528
Cell. 2015 Apr 23;161(3):595-609
pubmed: 25892225
Small. 2019 Nov;15(46):e1903746
pubmed: 31553140
Expert Opin Ther Targets. 2007 May;11(5):695-705
pubmed: 17465726
Oncol Lett. 2021 May;21(5):369
pubmed: 33747225
Adv Mater. 2019 Dec;31(51):e1904639
pubmed: 31692128

Auteurs

Guihong Lu (G)

Department of Neurosurgery, Health Science Center, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, 518035, P. R. China.
State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, P. R. China.
ORCID: 0000-0002-9160-9588

Xiaojun Wang (X)

State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, P. R. China.
ORCID: 0000-0001-8983-3233

Feng Li (F)

State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, P. R. China.
School of Chemical Engineering, University of Chinese Academy of Sciences, Beijing, 100049, P. R. China.
ORCID: 0000-0002-0045-1501

Shuang Wang (S)

State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, P. R. China.
ORCID: 0000-0002-9189-602X

Jiawei Zhao (J)

State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, P. R. China.
ORCID: 0000-0003-3343-4676

Jinyi Wang (J)

Department of Neurosurgery, Health Science Center, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, 518035, P. R. China.
ORCID: 0000-0003-4548-7660

Jing Liu (J)

Department of Neurosurgery, Health Science Center, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, 518035, P. R. China.
ORCID: 0000-0002-2392-0454

Chengliang Lyu (C)

State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, P. R. China.
ORCID: 0000-0002-3999-3199

Peng Ye (P)

State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, P. R. China.
ORCID: 0000-0001-6265-0074

Hui Tan (H)

Department of Neurosurgery, Health Science Center, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, 518035, P. R. China. huitan@email.szu.edu.cn.
Pneumology Department, Shenzhen Children's Hospital, Shenzhen, 518026, P. R. China. huitan@email.szu.edu.cn.
ORCID: 0000-0001-7259-2648

Weiping Li (W)

Department of Neurosurgery, Health Science Center, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, 518035, P. R. China. wpli@szu.edu.cn.
ORCID: 0000-0002-4391-3112

Guanghui Ma (G)

State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, P. R. China. ghma@ipe.ac.cn.
School of Chemical Engineering, University of Chinese Academy of Sciences, Beijing, 100049, P. R. China. ghma@ipe.ac.cn.
ORCID: 0000-0001-9154-5556

Wei Wei (W)

State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, P. R. China. weiwei@ipe.ac.cn.
School of Chemical Engineering, University of Chinese Academy of Sciences, Beijing, 100049, P. R. China. weiwei@ipe.ac.cn.
ORCID: 0000-0002-6244-3187

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Technologie, industrie et agriculture › Technologie › Biotechnologie › Biomimétique › Engineered biomimetic nanoparticles achieve...
questionsmedicales.fr › Maladies du système nerveux › Tumeurs du système nerveux › Tumeurs du système nerveux central › Tumeurs du cerveau › Engineered biomimetic nanoparticles achieve...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Engineered biomimetic nanoparticles achieve...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs du tissu nerveux › Tumeurs neuroectodermiques › Tumeurs neuroépitheliales › Gliome › Astrocytome › Glioblastome › Engineered biomimetic nanoparticles achieve...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs du tissu nerveux › Tumeurs neuroectodermiques › Tumeurs neuroépitheliales › Gliome › Engineered biomimetic nanoparticles achieve...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Engineered biomimetic nanoparticles achieve...
questionsmedicales.fr › Composés chimiques organiques › Radicaux libres › Peroxydes › Peroxyde d'hydrogène › Engineered biomimetic nanoparticles achieve...
questionsmedicales.fr › Technologie, industrie et agriculture › Produits manufacturés › Nanostructures › Nanoparticules › Engineered biomimetic nanoparticles achieve...